03/23/2021Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies
02/18/2021Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
02/03/2021Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment
02/01/2021Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus
12/10/2020Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
10/13/2020Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
